Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 25Gastrointestinal 22CNS 21Dermatologic 13Breast 10Other solid neoplasm 7Tumor-Agnostic 5Sarcoma 5Head & Neck 4Other hematologic neoplasm 3Lymphoid 3Endocrine 3Myeloid 2Genitourinary 2Plasma cell 1Gynecologic 1

Conditions

Thyroid Neoplasms 2Thyroid Cancer, Papillary 2Differentiated Thyroid Cancer 1Adenocarcinoma, Follicular 1

Interventions

Everolimus 59lutetium Lu 177 dotatate 46Magnetic Resonance Spectroscopy 33pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 24lanreotide 23cabozantinib 22pasireotide 21gallium Ga 68 dotatate 21lenvatinib 20Etoposide 19Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18Sunitinib 17Bevacizumab 16trametinib 15dabrafenib 15Doxorubicin 143-Iodobenzylguanidine 14surufatinib 13Sorafenib 13Ipilimumab 13Thyrotropin Alfa 12Injections 12Positron Emission Tomography Computed Tomography 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × AZD 6244 × Endocrine × Clear all
NCT02393690 2024-07-26

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

Academic and Community Cancer Research United

Phase 2 Completed
60 enrolled 12 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT01843062 2019-08-28

ASTRA

AstraZeneca

Phase 3 Terminated
233 enrolled 14 charts
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT00559949 2017-01-30

Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine

National Cancer Institute (NCI)

Phase 2 Completed
39 enrolled 8 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡